Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin TO THE EDITOR range: 0.1-2.0 years) compared to the non-DS patients (5.5 years; 0.2-19 years; P = 0.01) as has been reported previously 2 The recent study by Creutzig et al 1 reporting the outcome of although the white blood cell (WBC) counts between the two Down syndrome (DS) children with acute myeloid leukemia groups were not statistically different (WBC × 10 3 /mm 3 ) DS (AML) treated on AML-BFM (Berlin-Frankfurt-Mü nster) protopatients median 18.6; range: 3.8-289.9; non-DS patients: cols, 1 highlights the recent observation that DS children with 21.6; 0.7-232; P = 0.82). The relationship of in vitro drug AML have significantly higher event-free survival (EFS) rates sensitivity to treatment outcome is not known for this group compared to non-DS AML patients as first reported by the of patients since this study is still ongoing, although it can be Pediatric Oncology Group (POG) in 1992. 2 The improved strongly speculated that the DS patients will continue to have response rate to therapy of DS patients coincided with the use significantly high EFS rates compared to non-DS patients. of high-dose cytosine arabinoside (Ara-C) for intensification;
The mechanism of increased chemotherapy sensitivity of high-dose Ara-C intensification was also utilized in the POG, DS children is likely due to the presence of three copies of Children's Cancer Group (CCG) and Nordic Society of Pedichromosome 21 in DS cells and the localization of specific atric Hematology and Oncology (NOPHO) AML studies genes to chromosome 21 which modulate the activity of both which DS patients were treated on.
2,3,4
Ara-C and daunorubicin. The basis of enhanced chemotherapy response of DS chilIncreased activity of cystathionine-␤-synthase localized to dren was examined in vitro, by assessing the sensitivity of 21q22.3 6 may enhance Ara-C metabolism by: (1) altering myeloblasts (obtained from newly diagnosed patients with reduced folate pools leading to decreased deoxycytidine tri-AML registered on the POG 9421 protocol) to Ara-C and dauphosphate (dCTP) pools, and release of feedback inhibition on norubicin utilizing the MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-deoxycytidine kinase (dCk), the rate limiting phosphorylating diphenyltetrazolium bromide) cytotoxicity assay.
enzyme of Ara-C; and (2) increased expression of the dCk The MTT assay was based on the method of Pieters et al. 5 gene through hypomethylation 7 as a result of low homocys-A total of 77 patient samples were studied, of which 18 teine levels 8 and potential aterations in methionine and Ssamples were not included in the final analysis due to low adenosylmethionine levels. 9 We have previously reported that control cell viabilities (less than 75%) after 72 h. A total of DS myeloblasts and EBV-transformed lymphoblastoid cell eight DS patient samples were examined including one samlines with trisomy 21 generate significantly higher levels of ple from a DS infant with the transient myeloproliferative disthe active intracellular Ara-C metabolite, cytosine arabinoside order; all DS patients had the megakaryocytic (M 7 ) phenotype.
triphosphate (Ara-CTP), compared to non-DS cells following The DS myeloblasts were significantly more sensitive in in vitro incubation with 3 H-Ara-C, and DS cells have lower vitro to both Ara-C and daunorubicin compared to non-DS endogenous levels of dCTP which enhances Ara-C cytomyeloblasts (Table 1 ). There were no differences in the pertoxicity. 10 centage of cells in S-phase between the two groups, a factor An important aspect of the pathophysiology of DS is oxidathat may be relevant to S-phase-specific drugs such as Ara-C.
tive damage due to imbalances in oxygen-free radicals caused The DS patients were younger in age (median: 1.7 years; by increased activity of zinc/copper superoxide dismutase (SOD) localized to 21q22.1. 11 The carbonyl reductase (CBR) Table 1 In vitro sensitivity of myeloblasts to Ara-C and daunogene localized to 21q22.1 12 catalyzes the reduction of daunorubicin rubicin to the metabolite daunorubicinol. 13 Daunorubicin and other anthracyclines mediate their cytotoxicity via several
DS
Non-DS P value mechanisms including the generation of oxygen-free radicals,
thus the free radical imbalance in DS cells may enhance the cytotoxicity of daunorubicin and the prolonged exposure of The Barbara Ann Karmanos Cancer Institute, 
